BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033

BRCA Tests Market Report Overview

The BRCA Tests market size was $12.9 million in 2023. The market is expected to grow at a CAGR of more than 3% during 2023-2033.

Breast cancer type 1 (BRCA1) and Breast cancer type 1 (BRCA1 gene tests, under the overall umbrella of BRCA Tests) are carried out to detect gene rearrangements within blood samples. The outcome of this may guide therapies and prophylactic actions to treat or prevent certain types of breast and ovarian cancer. BRCA tests include Sanger sequencing Tests, Multiplex Ligation-dependent Probe Amplification (MLPA) Tests, and Other BRCA Tests.

BRCA Tests Market Outlook, 2023-2033 ($ Million)

Buy Full Report For More Insights into The BRCA Tests Market Forecast

Download a Free Report Sample

The BRCA Tests market research report has been created to understand the market behavior, which will help identify quantitative market trends within the In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on the BRCA Tests market for the year 2020 and beyond. The report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing in-licensing and out-licensing strategies.

BRCA Tests Market Dynamics

Rates of BRCA1/2 testing have increased in recent years. This is owing to lowered costs associated with BRCA1/2 screening, increased public awareness, and the availability of PARP inhibitors to treat breast and ovarian cancer patients with BRCA1/2 mutations.

Public awareness of BRCA1/2 is also increasing among the general public, resulting in patient-led advocacy for genetic testing. This increased awareness is, in part, because a high-profile celebrity underwent a double mastectomy in 2013 after testing positive for the BRCA1 mutation.

In addition to the above, the rising popularity of direct-to-consumer genetic testing, from companies such as 23andMe, will facilitate the increase in the BRCA1/2 testing rates. Moreover, individuals can access their BRCA1/2 status via companies that perform third-party re-analysis of data generated by non-health-related tests. As this approach produces a high rate of false positives, there is a recognized need amongst medical professionals to confirm any positive findings in a clinical laboratory.

BRCA Tests Market Segments

The BRCA Tests market can be segmented into Next Generation Sequencing (NGS) Tests and BRCA Tests. Next Generation Sequencing (NGS) Tests led the BRCA Tests market in 2023. It refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice. The technique is highly scalable and typically involves fragmenting the genome and then randomly sampling for and sequencing these fragments. NGS can be performed on formalin-fixed and paraffin-embedded (FFPE) and freshly collected tissue specimens and on fine-needle aspiration samples and small biopsy specimens.

BRCA Tests Market Analysis by Segments, 2023 (%)

Buy Full Report For More Insights into The BRCA Tests Market Segments

Download a Free Report Sample

BRCA Tests Market Segmentation by Regions

The key regions in the BRCA Tests market are North America, Europe, Asia Pacific, South America, and the Middle East and Africa. Europe accounted for the largest share of the BRCA Tests market revenue in 2023. GlobalData expects the BRCA1/2 testing rates for breast and ovarian cancer patients to increase in Europe, during the forecast period. The European Society for Medical Oncology (ESMO), including 26 European countries, recommends BRCA1/2 testing for all high-grade ovarian cancer patients who may benefit from PARP inhibitor therapy.

In Europe, NGS is routinely being used to identify BRCA1/2 mutations. Many other techniques such as aCGH are mostly absent in this region. GlobalData predicts that the declining costs of this technology will continue to support the growth of the NGS tests. The increasing ability of this technique to detect less common mutations such as LGRs will also positively impact the market growth in the coming years.

BRCA Tests Market Analysis by Regions, 2023 (%)

Buy the Full Report For More Insights into The BRCA Tests Market Regions

Download a Free Report Sample

BRCA Tests Market - Competitive Landscape

Some of the leading companies in the BRCA Tests market are:

• MRC-Holland BV
• Agilent Technologies Inc
• Illumina Inc
• Qiagen NV
• Takara Bio Inc

MRC-Holland BV is leading in the BRCA Tests market in 2023. It is followed by Agilent Technologies Inc.

BRCA Tests Market Analysis by Companies, 2023 (%)

Buy the Full Report For More Insights into The BRCA Tests Market Companies

Download a Free Report Sample

Segments Covered in the Report

BRCA Tests Segments Outlook (Value, $ Million, 2015-2033)

• Next Generation Sequencing (NGS) Tests
• BRCA Tests

BRCA Tests Regional Outlook (Value, $ Million, 2015-2033)

• North America
• Europe
• Asia Pacific
• South America
• Middle East and Africa

Key Inclusions

Key Inclusions of the market model are:

Currently marketed BRCA Tests Tests and evolving competitive landscape:

– Insightful review of the key industry trends.

– Annualized total BRCA Tests Tests market revenue by segment and market outlooks from 2015-2033.

– Market-level data on units, average selling prices, and market values.

Global, Regional, and Country level market specific insights:

– Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.

– SWOT analysis for the BRCA Tests market.

– Competitive dynamics insights and trends provided for the BRCA Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

– Country-specific overview of the healthcare system.

– Country-specific reimbursement policies.

– Country-specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: NGeneBio Co Ltd, Agilent Technologies Inc, Illumina Inc, NimaGen BV, Qiagen NV, Takara Holdings Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, MRC-Holland BV, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for –

• CMO executives who must have a deep understanding of the BRCA Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to –

• Understand the impact of COVID-19 on the BRCA Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the BRCA tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRCA tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRCA tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.